SG145716A1 - Amorphous rapamycin 42-ester with 3-hydroxy-2- (hydroxymethyl)-2- methylpropionic acid and pharmaceutical compositions containing the same - Google Patents

Amorphous rapamycin 42-ester with 3-hydroxy-2- (hydroxymethyl)-2- methylpropionic acid and pharmaceutical compositions containing the same

Info

Publication number
SG145716A1
SG145716A1 SG200805820-8A SG2008058208A SG145716A1 SG 145716 A1 SG145716 A1 SG 145716A1 SG 2008058208 A SG2008058208 A SG 2008058208A SG 145716 A1 SG145716 A1 SG 145716A1
Authority
SG
Singapore
Prior art keywords
hydroxymethyl
hydroxy
ester
pharmaceutical compositions
same
Prior art date
Application number
SG200805820-8A
Other languages
English (en)
Inventor
Eric J Benjamin
Muhammad Ashraf
Ashwinkumar Jain
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34272870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG145716(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of SG145716A1 publication Critical patent/SG145716A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
SG200805820-8A 2003-09-03 2004-08-16 Amorphous rapamycin 42-ester with 3-hydroxy-2- (hydroxymethyl)-2- methylpropionic acid and pharmaceutical compositions containing the same SG145716A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49978903P 2003-09-03 2003-09-03

Publications (1)

Publication Number Publication Date
SG145716A1 true SG145716A1 (en) 2008-09-29

Family

ID=34272870

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200805820-8A SG145716A1 (en) 2003-09-03 2004-08-16 Amorphous rapamycin 42-ester with 3-hydroxy-2- (hydroxymethyl)-2- methylpropionic acid and pharmaceutical compositions containing the same

Country Status (25)

Country Link
US (2) US7271177B2 (es)
EP (1) EP1660081A1 (es)
JP (1) JP2007504226A (es)
KR (1) KR20060090803A (es)
CN (1) CN1874771A (es)
AR (1) AR045559A1 (es)
AU (1) AU2004270154A1 (es)
BR (1) BRPI0414066A (es)
CA (1) CA2536775A1 (es)
CO (1) CO5680426A2 (es)
CR (1) CR8293A (es)
EC (1) ECSP066473A (es)
GT (1) GT200400175A (es)
IL (1) IL173786A0 (es)
MX (1) MXPA06002123A (es)
NO (1) NO20061048L (es)
PA (1) PA8611201A1 (es)
PE (1) PE20050945A1 (es)
RU (1) RU2345999C2 (es)
SA (1) SA04250334B1 (es)
SG (1) SG145716A1 (es)
TW (1) TW200510428A (es)
UA (1) UA84881C2 (es)
WO (1) WO2005023254A1 (es)
ZA (1) ZA200601822B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007504226A (ja) * 2003-09-03 2007-03-01 ワイス 非晶質状のラパマイシンの３−ヒドロキシ−２−（ヒドロキシメチル）−２−メチルプロピオン酸との４２−エステル、およびそれを含むその医薬組成物
ES2298861T3 (es) * 2004-01-08 2008-05-16 Wyeth Composicion farmaceutica que puede obtenerse mediante compresion directa para la administracion oral de cci-779.
US7349971B2 (en) * 2004-02-05 2008-03-25 Scenera Technologies, Llc System for transmitting data utilizing multiple communication applications simultaneously in response to user request without specifying recipient's communication information
AU2005238431A1 (en) 2004-04-14 2005-11-10 Wyeth Regiospecific synthesis of rapamycin 42-ester derivatives
CA2562164A1 (en) * 2004-04-27 2005-11-10 Wyeth Labeling of rapamycin using rapamycin-specific methylases
JP5117190B2 (ja) 2004-08-27 2013-01-09 コーディス・コーポレイション 溶媒を含有しない非晶質ラパマイシン
MX2007003731A (es) * 2004-09-29 2007-08-14 Johnson & Johnson Formas de dosis farmaceuticas de compuestos similares a rapamicina amorfos estables.
US7442707B2 (en) 2005-02-09 2008-10-28 Wyeth CCI-779 polymorph and use thereof
CN101321770A (zh) * 2005-12-07 2008-12-10 惠氏公司 由雷帕霉素42-酯硼酸酯制备雷帕霉素42-酯的可放大方法
JP2009518413A (ja) * 2005-12-07 2009-05-07 ワイス 精製結晶性ｃｃｉ−７７９を調製するためのプロセス
JP2009518648A (ja) * 2005-12-07 2009-05-07 ワイス 結晶性ラパマイシンを調製するための方法およびを示差走査熱量測定使用してラパマイシン化合物の結晶化度を測定するための方法
CN101304970A (zh) * 2005-12-21 2008-11-12 卫材R&D管理有限公司 1，2-二氢吡啶化合物的无定形物
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US20080234657A1 (en) * 2007-03-22 2008-09-25 Medtronic Vascular, Inc. Methods for contributing to cardiovascular treatments
JP2008305262A (ja) * 2007-06-08 2008-12-18 Konica Minolta Business Technologies Inc サーバ及びシンクライアント環境でのプリンタ紹介方法
US8852620B2 (en) 2007-07-20 2014-10-07 Medtronic Vascular, Inc. Medical devices comprising polymeric drug delivery systems with drug solubility gradients
US20090269480A1 (en) * 2008-04-24 2009-10-29 Medtronic Vascular, Inc. Supercritical Fluid Loading of Porous Medical Devices With Bioactive Agents
WO2010024898A2 (en) 2008-08-29 2010-03-04 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
PT2365802T (pt) 2008-11-11 2017-11-14 Univ Texas Microcápsulas de rapamicina e utilização para o tratamento de cancro
US20100227799A1 (en) * 2009-03-09 2010-09-09 Medtronic Vascular, Inc. Simultaneous photodynamic therapy and photo induced polymerization
AU2010247766B2 (en) 2009-05-12 2015-05-21 Corcept Therapeutics, Inc. Solid forms and process for preparing
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
US8829024B2 (en) 2011-01-07 2014-09-09 Corcept Therapeutics, Inc. Combination steroid and glucocorticoid receptor antagonist therapy
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
WO2014160328A1 (en) 2013-03-13 2014-10-02 The Board Of Regents Of The University Of Texas System Mtor inhibitors for prevention of intestinal polyp growth
US9951009B2 (en) * 2013-08-29 2018-04-24 Cadila Healthcare Limited Polymorphic form of pyrrole derivative and intermediate thereof
ES2869172T3 (es) 2013-11-25 2021-10-25 Corcept Therapeutics Inc Moduladores del receptor de glucocorticoides de azadecalina condensada con octahidro
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
EP3089737B1 (en) 2013-12-31 2021-11-03 Rapamycin Holdings, LLC Oral rapamycin nanoparticle preparations and use
AU2018244928B2 (en) 2017-03-31 2023-10-19 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat cervical cancer
EP3624863B1 (en) 2017-05-15 2021-04-14 C.R. Bard, Inc. Medical device with drug-eluting coating and intermediate layer
JP7262581B2 (ja) 2018-11-14 2023-04-21 ルトニックス，インコーポレーテッド 改質されたデバイス表面に薬物溶出コーティングを有する医療用デバイス
BR112021010461A2 (pt) 2018-12-19 2021-08-24 Corcept Therapeutics Incorporated Formulação e dose unitária para administração oral de relacorilante
US11234971B2 (en) 2018-12-19 2022-02-01 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
US11389432B2 (en) 2018-12-19 2022-07-19 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
WO2020172501A1 (en) 2019-02-22 2020-08-27 Corcept Therapeutics Incorporated Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator
CN113939324A (zh) 2019-04-08 2022-01-14 巴德外周血管股份有限公司 在经改性装置表面上具有药物洗脱涂层的医疗装置
CA3158745A1 (en) 2019-12-11 2021-06-17 Corcept Therapeutics Incorporated Methods of treating antipsychotic-induced weight gain with miricorilant

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
BE1009856A5 (fr) * 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
US5989591A (en) * 1997-03-14 1999-11-23 American Home Products Corporation Rapamycin formulations for oral administration
TWI256395B (en) * 1999-09-29 2006-06-11 Wyeth Corp Regioselective synthesis of rapamycin derivatives
CN100415233C (zh) * 2002-09-17 2008-09-03 惠氏公司 口服制剂
RU2339639C2 (ru) * 2003-08-07 2008-11-27 Уайт Региоселективный синтез cci-779
JP2007504226A (ja) 2003-09-03 2007-03-01 ワイス 非晶質状のラパマイシンの３−ヒドロキシ−２−（ヒドロキシメチル）−２−メチルプロピオン酸との４２−エステル、およびそれを含むその医薬組成物
ES2298861T3 (es) 2004-01-08 2008-05-16 Wyeth Composicion farmaceutica que puede obtenerse mediante compresion directa para la administracion oral de cci-779.

Also Published As

Publication number Publication date
ECSP066473A (es) 2006-10-10
US7446111B2 (en) 2008-11-04
BRPI0414066A (pt) 2006-10-24
AR045559A1 (es) 2005-11-02
IL173786A0 (en) 2006-07-05
UA84881C2 (ru) 2008-12-10
PA8611201A1 (es) 2005-05-10
US20080070950A1 (en) 2008-03-20
RU2006110568A (ru) 2007-10-10
CR8293A (es) 2006-07-14
AU2004270154A1 (en) 2005-03-17
EP1660081A1 (en) 2006-05-31
PE20050945A1 (es) 2005-12-14
US7271177B2 (en) 2007-09-18
CA2536775A1 (en) 2005-03-17
ZA200601822B (en) 2008-12-31
JP2007504226A (ja) 2007-03-01
RU2345999C2 (ru) 2009-02-10
KR20060090803A (ko) 2006-08-16
WO2005023254A1 (en) 2005-03-17
GT200400175A (es) 2005-04-18
NO20061048L (no) 2006-05-24
TW200510428A (en) 2005-03-16
CN1874771A (zh) 2006-12-06
MXPA06002123A (es) 2006-05-17
CO5680426A2 (es) 2006-09-29
US20050049271A1 (en) 2005-03-03
SA04250334B1 (ar) 2008-05-19

Similar Documents

Publication Publication Date Title
SG145716A1 (en) Amorphous rapamycin 42-ester with 3-hydroxy-2- (hydroxymethyl)-2- methylpropionic acid and pharmaceutical compositions containing the same
HK1084050A1 (en) Granulate formulation of the rapamycin ester cci-779
NO20050455L (no) Parenterale formuleringer inneholdende en rapamycinhydroksyester
MX2007005221A (es) Formas cristalinas de ascomicina y preparacion de ellas.
TW200602036A (en) Diphenylazetidone derivates
HUP0400521A2 (hu) A CCI-779 alkalmazása daganatellenes szerként
WO2007028135A3 (en) Imidazopyridine compounds
BRPI0518079A (pt) usos de um inibidor de mtor, de uma rapamicina, e de 42-éster de rapamicina com ácido 3-hidróxi-2- (hidroximetil) -2-metilpropiÈnico, composição farmacêutica, e, embalagem farmacêutica
EP1938691A3 (en) Nematicidal compositions
WO2004063289A3 (en) Surface modification of carbonaceous materials with tri substituted aminoalkyl substituents
WO2007056175A3 (en) 41-methoxy isotope labeled rapamycin 42-ester
WO2004087073A3 (en) Treatment of demyelinating conditions
CL2007002988A1 (es) Proceso para la preparacion de un isomero individual de rapamicina 42 ester con acido 3-hidroxi-2-(hidroximetil)-2-metilpropionico (cci-779) monopegilado.
WO2002076396A3 (en) Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
UA83697C2 (ru) Cci-779 для лечения лимфомы из мантийных клеток
WO2003099783A3 (en) Tropane compounds
AU2003285261A1 (en) Compositions for the treatment of mycobacterial infections
AU2003249986A1 (en) Piece of equipment for an infantryman
UA67578A (en) Antibacterial substance
AU2003269472A1 (en) Process for the preparation of an enzyme composition
RS20050620A (en) Nitrate esters of phenylaminothiophenacetic acid derivatives